Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole liver iron overload measured by Magnetic Iron Detector in thalassemia and MDS patients treated with deferasirox
2009-010088-17Phase 4Active
- Sponsor
- Ospedali Galliera
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in beta thalassemia major, myelodysplastic syndrome (MDS) and Congenital Anemia, sponsored by Ospedali Galliera. Primary endpoint: Whole liver iron overload change measured by MID. Started Apr 2009; status: active.
02
Drugs
deferasirox
03
Conditions
beta thalassemia majormyelodysplastic syndrome (MDS)Congenital Anemia
Beyond the preview
Go deeper on 2009-010088-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010088-17.